Responses
Oral Abstracts
Awards Ceremony & Plenary 4: Seminal Abstract Presentations
O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study
Compose a Response to This Article
Other responses
No responses have been published for this article.